The MANTICORE 101- trial was conducted in HER2-positive BC patients to study the efficacy of the combination of ACE inhibitors and β-blockers in preventing trastuzumab-mediated cardiotoxicity. The gene discussed is ERBB2; the disease is breast cancer.